Treatment discontinuation associated with perioperative toxicity of FLOT versus XELOX chemotherapy in patients with resectable gastric cancer: prospective randomized trial (PECORINO).

ABSTRACT:

Background

Gastric cancer represents a significant global health burden, necessitating effective multimodal treatment approaches. Neoadjuvant chemotherapy has gained prominence in improving outcomes, with FLOT (5-fluorouracil, leucovorin, oxaliplatin and docetaxel) and XELOX (capecitabine and oxaliplatin) emerging as potential regimens. This study aims to compare the efficacy and safety of neoadjuvant FLOT and XELOX in resectable gastric cancer.

Methods

We conducted a prospective randomized open-label clinical trial. Sixty-nine patients with resectable gastric cancer were randomly assigned to perioperative 8 cycles of FLOT and 8 cycles of XELOX and curative surgery. The primary endpoint was the proportion of patients who fully adhered to all the allocated treatment per proto

SUBMITTER: Dobrzhanskyi O 

PROVIDER: S-EPMC12260966 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature